Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 24798681)

1.

Pharmacological and Toxicological Effects of Lithium in Zebrafish.

Siebel AM, Vianna MR, Bonan CD.

ACS Chem Neurosci. 2014 May 14. [Epub ahead of print]

PMID:
24798681
2.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
3.

Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge.

Ikonomov OC, Manji HK.

Am J Psychiatry. 1999 Oct;156(10):1506-14. Review.

PMID:
10518159
4.

Sustained behavioral effects of lithium exposure during early development in zebrafish: involvement of the Wnt-β-catenin signaling pathway.

Nery LR, Eltz NS, Martins L, Guerim LD, Pereira TC, Bogo MR, Vianna MR.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Dec 3;55:101-8. doi: 10.1016/j.pnpbp.2014.04.011. Epub 2014 May 6.

PMID:
24813569
5.

Signal transduction pathways. Molecular targets for lithium's actions.

Manji HK, Potter WZ, Lenox RH.

Arch Gen Psychiatry. 1995 Jul;52(7):531-43. Review.

PMID:
7598629
6.

Inhibition of GSK3 by lithium, from single molecules to signaling networks.

Freland L, Beaulieu JM.

Front Mol Neurosci. 2012 Feb 20;5:14. doi: 10.3389/fnmol.2012.00014. eCollection 2012 Jan 27.

7.

Lithium: still a major option in the management of bipolar disorder.

Licht RW.

CNS Neurosci Ther. 2012 Mar;18(3):219-26. doi: 10.1111/j.1755-5949.2011.00260.x. Epub 2011 Jun 23. Review.

PMID:
22070642
8.

Lithium-mediated protection against ethanol neurotoxicity.

Luo J.

Front Neurosci. 2010 Jun 28;4:41. doi: 10.3389/fnins.2010.00041. eCollection 2010.

9.

Lithium for older adults with bipolar disorder: Should it still be considered a first-line agent?

Shulman KI.

Drugs Aging. 2010 Aug 1;27(8):607-15. doi: 10.2165/11537700-000000000-00000.

PMID:
20658789
10.
11.

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Chiu CT, Chuang DM.

Pharmacol Ther. 2010 Nov;128(2):281-304. doi: 10.1016/j.pharmthera.2010.07.006. Epub 2010 Aug 10. Review.

12.

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J.

Cochrane Database Syst Rev. 2013 Oct 17;10:CD003196. doi: 10.1002/14651858.CD003196.pub2. Review.

PMID:
24132760
13.

Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Rybakowski JK.

CNS Drugs. 2013 Mar;27(3):165-73. doi: 10.1007/s40263-013-0040-7. Review.

14.

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM.

Cochrane Database Syst Rev. 2001;(3):CD003196. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD003196.

PMID:
11687047
15.

Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Malhi GS, Tanious M, Das P, Coulston CM, Berk M.

CNS Drugs. 2013 Feb;27(2):135-53. doi: 10.1007/s40263-013-0039-0. Review.

PMID:
23371914
16.

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R.

Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. Review.

17.

Molecular effects of lithium.

Quiroz JA, Gould TD, Manji HK.

Mol Interv. 2004 Oct;4(5):259-72. Review.

PMID:
15471909
18.

[Alpha-interferon and mental disorders].

Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D.

Encephale. 2001 Jul-Aug;27(4):308-17. Review. French.

PMID:
11686052
19.

Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium.

Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS.

J Circadian Rhythms. 2007 Feb 12;5:3.

20.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N.

Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk